背景:具有慢性丙型肝炎基因型1(HCV-1)和难以治疗特征的患者对聚乙二醇化干扰素α和利巴韦林(RBV)的反应较差,并可能受益于活性增加的干扰素(共识干扰素或CIFN),从每日给药有利的病毒动力学,和更长的治疗时间。这项初步研究的目的是确定dailyCIFNRBV用于HCV-1感染患者的初始治疗的有效性和安全性。
方法:具有难以治疗特征的患者(92%为男性,33%非洲裔美国人,78%的退伍军人事务部[VA];67%的高病毒载量,59%3-4期纤维化,在七个VA和两个社区医疗中心登记,平均体重为204磅)。他们被随机分为每日CIFN(15mcg/天SQ)和RBV(1-1.2g/天PO),持续52周(A组,n=33)或52-72周(从病毒应答时间+48周开始)(B组,n=31)。
结果:治疗组A和B的意向治疗分析显示33%(11/33)和32%(10/31)持续病毒学应答(SVR),分别。B组仅2/31患者接受超过52周的治疗。整体组表现出31%(20/64)的快速病毒学应答率(RVR),54%(34/64)的治疗结束病毒学应答和33%(21/64)的SVR。RVR患者在4周时,早期病毒学应答从8-12周,16-24周的晚期病毒学应答显示SVR为75%(15/20),31%(4/13),和22%(2/9),分别。26/64(40%)患者发生了整体早期非协议停药。
结论:初始治疗HCV-1患者的DailyCIFN和利巴韦林有可能达到相对较高的RVR率,但停药是常见的,成功使用该方案在很大程度上依赖于足够的患者支持来维持依从性.
BACKGROUND: Patients with chronic hepatitis C genotype 1 (HCV-1) and difficult-to-treat characteristics respond poorly to pegylated interferon alfa and ribavirin (RBV), and could benefit from an interferon with increased activity (
consensus interferon or CIFN), favorable viral kinetics from daily dosing, and a longer duration of therapy. The purpose of this pilot study was to determine the efficacy and safety of daily CIFN + RBV for initial treatment of patients with HCV-1 infection.
METHODS: Patients with difficult-to-treat characteristics (92% male, 33% African American, 78% Veterans Affairs [VA]; 67% high viral load, 59% stage 3-4 fibrosis, and mean weight of 204 lbs) were enrolled at seven VA and two community medical centers. They were randomized to daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B, n = 31).
RESULTS: Intention to treat analysis for treatment groups A and B demonstrated 33% (11/33) and 32% (10/31) sustained virologic response (SVR), respectively. Only 2/31 patients in group B received more than 52 weeks of treatment. The overall group demonstrated a 31% (20/64) rapid virologic response rate (RVR), 54% (34/64) end of treatment virologic response and a 33% (21/64) SVR. Patients with RVR at 4 weeks, early virologic response from 8-12 weeks, and late virologic response from 16-24 weeks demonstrated SVR of 75% (15/20), 31% (4/13), and 22% (2/9), respectively. Overall early non-protocol discontinuation occurred in 26/64 (40%) patients.
CONCLUSIONS: Daily CIFN and ribavirin for initial treatment of HCV-1 patients has potential for achieving a relatively high RVR rate, but discontinuations are frequent and successful use of this regimen is highly dependent on adequate patient support to maintain adherence.